Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy.
Transplantation
; 66(12): 1732-5, 1998 Dec 27.
Article
em En
| MEDLINE
| ID: mdl-9884268
ABSTRACT
BACKGROUND:
Initial doses of OKT3 are associated with a cytokine-induced acute clinical syndrome (ACS). This study assessed the safety of a recombinant human tumor necrosis factor receptor fusion protein (TNFRFc) given to minimize OKT3-ACS symptoms in renal allograft recipients undergoing induction therapy.METHODS:
Sixteen patients were randomized into treatment or control groups. Treated patients received TNFRFc 1 hr before OKT3 on days 0 and 3. Patients were monitored after transplant for OKT3-ACS symptoms. Levels of cytokines, serum creatinine, and C-reactive protein were followed.RESULTS:
Patients receiving TNFRFc had lower OKT3-ACS symptoms as measured by a scoring system. There was a higher incidence of infection in treated patients (10/12) compared to controls (1/4) in the 3 months after transplant, but the etiology of this difference was unclear. There were no significant differences in cytokine profiles.CONCLUSIONS:
TNFRFc is well tolerated by renal transplant patients receiving OKT3 induction therapy and modestly decreases the symptoms associated with OKT3-ACS.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Fragmentos Fc das Imunoglobulinas
/
Transplante de Rim
/
Muromonab-CD3
/
Receptores do Fator de Necrose Tumoral
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
Transplantation
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos